Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053976 | 0.98 | LIMK1 (0.37) | LIMK1ALOX5APFEN1CA12CA1 | |
| SCHEMBL10053984 | 0.78 | HPGD (0.37) | LIMK1DHFR | |
| SCHEMBL14882575 | 0.78 | GABRA1 (0.36) | CA1CA2GABRA1GABRB2 | |
| SCHEMBL14225396 | 0.76 | GABRA1 (0.38) | CA1CA2GABRA1GABRB2 | |
| SCHEMBL10053973 | 0.76 | HPGD (0.38) | LIMK1DHFR | |
| SCHEMBL9174922 | 0.74 | GABRA1 (0.52) | CA12CA1CA2CA9DHFR | |
| SCHEMBL22675162 | 0.74 | DHFR (0.34) | LIMK1ALOX5APFEN1CA12CA1 | |
| SCHEMBL22675090 | 0.72 | ALOX5AP (0.35) | LIMK1ALOX5APFEN1CA12CA1 | |
| SCHEMBL10053974 | 0.72 | BACE1 (0.37) | LIMK1 | |
| SCHEMBL167078 | 0.72 | GABRA1 (0.55) | CA12CA1CA2CA9DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8982443-B2 | Organic compound and electrochromic device including the same | CANON KABUSHIKI KAISHA (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8982443-B2 | Organic compound and electrochromic device including the same | CANON KABUSHIKI KAISHA (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20130100517-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130100517-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-04-25 | — | — | US | disclosed |
| WO-2012002185-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130100517-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | CCNL2, DNMT3L, ARL1 | LIMK1 487/4885ALOX5AP 2078/4885FEN1 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.